Technical Analysis for CNTA - Centessa Pharmaceuticals plc

Grade Last Price % Change Price Change
F 17.965 -0.47% -0.09
CNTA closed down 1.1 percent on Wednesday, September 22, 2021, on 4.05 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical CNTA trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish -0.47%
Volume Surge Other -0.47%
Lower Bollinger Band Walk Weakness -0.47%
New 52 Week Low Weakness -0.47%
Wide Bands Range Expansion -0.47%
Lower Bollinger Band Touch Weakness -0.47%
Oversold Stochastic Weakness -0.47%
Slingshot Bearish Bearish Swing Setup -1.56%
Stochastic Buy Signal Bullish -1.56%
Doji - Bullish? Reversal -1.56%
Older End-of-Day Signals for CNTA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % 2 minutes ago
Lower Bollinger Band Support 2 minutes ago
60 Minute Opening Range Breakdown 22 minutes ago
Down 1% 22 minutes ago
Up 3% about 1 hour ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Centessa Pharmaceuticals plc Description

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.


Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Pharmaceutical Solid Tumors Drugs Immunotherapy Non Small Cell Lung Cancer Pulmonary Arterial Hypertension Epidermal Growth Factor Receptor Idiopathic Pulmonary Fibrosis Lung Cancer Hematological Malignancies Lupus Oncogenes Hemophilia A Narcolepsy Orphan Drugs Non Small Cell Lung Carcinoma Treatment Of Hemophilia Alpha 1 Antitrypsin Deficiency Cutaneous Squamous Cell Carcinoma

Is CNTA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 26.9
52 Week Low 17.36
Average Volume 139,377
200-Day Moving Average 0.00
50-Day Moving Average 20.83
20-Day Moving Average 20.94
10-Day Moving Average 20.08
Average True Range 1.58
ADX 15.25
+DI 12.81
-DI 22.72
Chandelier Exit (Long, 3 ATRs) 21.25
Chandelier Exit (Short, 3 ATRs) 22.09
Upper Bollinger Bands 24.14
Lower Bollinger Band 17.74
Percent B (%b) 0.05
BandWidth 30.55
MACD Line -0.72
MACD Signal Line -0.26
MACD Histogram -0.4663
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.47
Resistance 3 (R3) 20.51 19.74 20.07
Resistance 2 (R2) 19.74 19.13 19.72 19.93
Resistance 1 (R1) 18.90 18.75 19.32 18.86 19.80
Pivot Point 18.13 18.13 18.34 18.11 18.13
Support 1 (S1) 17.28 17.51 17.71 17.24 16.30
Support 2 (S2) 16.51 17.13 16.49 16.17
Support 3 (S3) 15.67 16.51 16.03
Support 4 (S4) 15.63